Latest Biotech News

Merck KGaA agreed to acquire Bio-Techne for about $11.3 billion, the company’s largest deal since its 2015 Sigma-Aldrich acquisition. The cash offer of $73 per share comes with a ~36% premium and...

Biogen moved to cut most of its pipeline work after acquiring Apellis Pharmaceuticals for $5.6 billion, pausing or canceling investment across the majority of Apellis programs that came with the...

RQ Bio secured an oversubscribed $115 million Series A to advance RQB01, a long-acting antibody program intended to provide broad, season-long protection against influenza in high-risk and...

Ollin Biosciences raised $330 million in a Series B as it prepares pivotal testing for an eye therapy targeting diabetic macular edema and wet age-related macular degeneration. The funding is...

Researchers at the University of Pennsylvania’s Perelman School of Medicine and Abramson Cancer Center used an AI, human-in-the-loop framework to nominate and validate a multi-cancer CAR T target....

Immunai inked a research collaboration with Boehringer Ingelheim valued at up to $15 million to identify novel T-cell targets across oncology and autoimmune disease. The partnership runs through...

Remix Therapeutics is set to go public via a reverse merger with Passage Bio, a gene therapy company co-founded by Jim Wilson. Under the agreement, the combined entity is expected to close in the...

Natera’s Signatera MRD assay gained regulatory approval in Japan from the Pharmaceuticals and Medical Devices Agency for colorectal cancer use in the neoadjuvant setting. The decision effectively...

At BIO 2026, FDA leadership emphasized workforce stabilization efforts after earlier staffing reductions, detailing plans to hire and retain personnel to reduce operational disruption. FDA acting...

Merck KGaA agreed to acquire Bio-Techne for about $11.3 billion, a move aimed at expanding the German company’s life-science footprint across multiomics, spatial biology, and advanced research...

The FDA expanded Gilead’s Trodelvy label for first-line triple-negative breast cancer, allowing use regardless of PD-L1 status and creating a new competitive front in the TROP2 ADC market. The...

Ionis Pharmaceuticals received FDA approval that further expands Tryngolza (olezarsen) for adults with severe hypertriglyceridemia, widening the drug’s commercial address. The approval came after...

A study in Cell reports an AI-enabled framework for nominating CAR T antigens, with preclinical validation of a lead candidate aimed at multi-cancer potential. Researchers at the University of...

Immune profiling company Immunai entered a research collaboration with Boehringer Ingelheim worth up to $15 million to identify novel T-cell targets across oncology and autoimmune disease. Immunai...

The Michael J. Fox Foundation awarded X-tosis a $2.74 million grant to advance XTS-001 toward clinical development for Parkinson’s disease. The funding will support confirmatory studies, biomarker...

Unixell Biotechnology obtained FDA IND clearance for UX-DA003, its allogeneic iPSC-derived therapy for Parkinson’s disease, enabling clinical development in the U.S. The company also reported IND...

RQ Bio secured an oversubscribed $115 million Series A to advance RQB01, a long-acting antibody program aimed at preventing seasonal influenza in high-risk and immunocompromised populations. The...

Researchers reported an engineered feeder cell line that sharply increases allogeneic NK cell production, addressing a major bottleneck in adoptive cell therapy manufacturing. Using an optimized...

Remix Therapeutics agreed to go public through a reverse merger with Passage Bio, with the combined company expected to trade under the Remix name and the ticker RMTX. Remix investors are slated...

Merck KGaA agreed to acquire Bio-Techne in an approximately $11.3 billion deal, the company said, positioning the combined platform to span discovery, translational research, and commercial...